Table 1 A summary of the baseline characteristics of total patient cohort (n = 86) included in the ceftriaxone 2 g and 4 g daily dosing groups
Clinical parameter | 2 g (n = 47) | 4 g (n = 39) | P value (< 0.05, 95% CI) |
|---|---|---|---|
Age (years), median (IQR) | 54.5 (69.75–40.25) | 54.5 (68.25–25.5) | 0.354 |
Gender (female) | 21 (44.7%) | 14 (35.9%) | 0.509 |
Duration of therapy (days) of OPAT, median (IQR) | 19 (33.75–14) | 20 (34.25–12.75) | 0.103 |
Co-morbidities | |||
Pre-established renal disease | 0 | 4 (10.2%) | 0.039 |
Pre-established liver disease | 1 (2.1%) | 0 | > 0.999 |
Pre-established haematological disease | 1 (2.1%) | 0 | > 0.999 |
Microbiology | |||
MSSA (mono-microbial) | 2 (4.3%) | 18 (46.15%) | < 0.0001 |
Other Staphylococcal species | 2 (4.3%) | 1 (2.6%) | > 0.999 |
Streptococcal species | 8 (17%) | 2 (5.1%) | 0.104 |
Enterobacterales | 2 (4.3%) | 0 | 0.498 |
Poly-microbial | 0 | 7 (17.9%) | 0.003 |
Anaerobes | 4 (8.5%) | 0 | 0.123 |
Other | 1 (2.1%) | 0 | > 0.999 |
Nil identified | 28 (59.6%) | 11 (28.2%) | 0.005 |
Indication | |||
Bone and joint infections | 15 (31.9%) | 26 (66.7%) | 0.002 |
Spinal nd central nervous system infections | 2 (4.3%) | 5 (12.8%) | 0.237 |
Skin and soft tissue infection | 2 (4.3%) | 6 (15.4%) | 0.133 |
Intra-abdominal infections | 9 (19.1%) | 1 (2.6%) | 0.019 |
Gynaecological infections | 8 (17.0%) | 0 | 0.007 |
Complex respiratory infections | 3 (6.4%) | 1 (2.6%) | 0.623 |
Infective endocarditis | 3 (6.4%) | 0 | 0.248 |
Liver abscess | 1 (2.1%) | 0 | > 0.999 |
Complex urinary tract infection | 2 (4.3%) | 0 | 0.499 |
Pyrexia of unknown origin | 2 (4.3%) | 0 | 0.499 |
Concurrent antimicrobials | |||
Metronidazole | 25 (53.2%) | 11 (28.2%) | 0.023 |
Rifampicin | 0 | 3 (7.7%) | 0.089 |
Clindamycin | 0 | 2 (5.1%) | 0.203 |
Fosfomycin | 1 (2.1%) | 0 | > 0.999 |
Teicoplanin | 1 (2.1%) | 0 | > 0.999 |
Doxycycline and metronidazole (combination) | 4 (8.5%) | 0 | 0.123 |
Antivirals | 0 | 1 (2.6%) | > 0.999 |
Antifungals | 0 | 0 | n/a |
Nil concurrent antimicrobials | 16 (41%) | 22 (56.4%) | 0.050 |